# 510(k) SUMMARY for EG V1 Pro Self Monitoring Glucose Test System

A. Submitter's information Company: EPS Bio Technology Corp. Address: No. 8, R&D RD. III, Hsinchu Science Park Hsinchu City, Taiwan, R.O.C. Contact Name: Mr. Y.C. Lei, General Manager Phone: 886-3-6686868 Fax: 886-3-6686866

B. Measured: Glucose

C. Type of Test: Quantitative; electrochemical biosensor

D. Proprietary and Established Names: EG V1 Pro Self-Monitoring Blood Glucose Test System

E. Common or Usual Name: Glucose Test System

F. Regulatory Information: 1.Requlation section: 21 CFR 862.1345, Glucose Test System 21 CFR 862.1660, Quality control materials (assayed and unassayed)

Classification: Class II Class I, reserved

.Product code: NBW, System Test, Blood Glucose, Over the Counter LFR, Glucose Dehydrogenase, Glucose JJX, Single (Specified) Controls (assayed and Unassayed)

4. Panel: Chemistry 75

# G. Intended Use:

1.Intended use(s): See Indications for Use below

2. Indication(s) for use:

The EG V1 Pro Self Monitoring Blood Glucose Test System is intended for the quantitative measurement of glucose in venous whole blood or fresh capillary whole blood from fingertip. Testing is done outside the body (In Vitro diagnostic use). It is intended for multiple-patient use in professional healthcare settings, as an aid to monitor the effectiveness of diabetes control. The system is only used with single-use lancing devices. The system is not to be used on neonates, nor for the diagnosis of, or screening for diabetes mellitus.

The system consists of the EG V1 Pro meter and the EG Pro test strips. The EG V1 Pro meter only is used with the EG Pro test strips to quantitatively measure glucose in venous whole blood or fresh capillary whole blood from fingertip.

The EG Glucose Control Solution   
For use with the EG V1 Pro Blood Glucose Self Monitoring System as a quality control check to verify the accuracy of blood glucose test results.

H. Device Description:

The EG V1 Pro Self-Monitoring Blood Glucose System consists of the EG V1 Pro Blood Glucose Meter, EG Pro Glucose Test Strips, single-use Lancing Device and EG Level 2 Control Solution. (Please refer to the IFU for the product picture)

I. Substantial Equivalence Information:

1. Predicate device name(s): ASCENSIA CONTOUR BLOOD GLUCOSE METER, MODEL 7151; REAGENT STRIP, MODEL 7080

Device Company BAYER HEALTHCARE

3. Predicate 510(k) number(s): k062058

4. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities            I</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Detection method</td><td colspan="1" rowspan="1">Amperometry</td><td colspan="1" rowspan="1">Amperometry</td></tr><tr><td colspan="1" rowspan="1">Enzyme</td><td colspan="1" rowspan="1">Glucose Dehydrogenase(FAD)</td><td colspan="1" rowspan="1">Glucose Dehydrogenase(FAD)</td></tr><tr><td colspan="1" rowspan="1">Sample volume</td><td colspan="1" rowspan="1">≥ 0.6 uL</td><td colspan="1" rowspan="1">≥ 0.6 uL</td></tr><tr><td colspan="1" rowspan="1">Temperature range</td><td colspan="1" rowspan="1">10-40°C</td><td colspan="1" rowspan="1">10-40°C</td></tr><tr><td colspan="1" rowspan="1">Memory capability</td><td colspan="1" rowspan="1">480 tests with date andtime</td><td colspan="1" rowspan="1">480 tests with date andtime</td></tr><tr><td colspan="1" rowspan="1">Hematocrit range</td><td colspan="1" rowspan="1">20-60%</td><td colspan="1" rowspan="1">20-60%</td></tr><tr><td colspan="1" rowspan="1">Power</td><td colspan="1" rowspan="1">3V CR2032 batteries</td><td colspan="1" rowspan="1">3V CR2032 batteries</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Test range</td><td colspan="1" rowspan="1">20-600 mg/dL</td><td colspan="1" rowspan="1">10-600 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Anatomical Sites</td><td colspan="1" rowspan="1">Venous sample andCapillary samples from thefingertip, palm, forearm,</td><td colspan="1" rowspan="1">Capillary samples from thefingertip, palm, forearm,abdomen and thigh</td></tr><tr><td colspan="1" rowspan="1">Test time</td><td colspan="1" rowspan="1">5 seconds</td><td colspan="1" rowspan="1">8 seconds</td></tr><tr><td colspan="1" rowspan="1">Size L x W x H (inch)</td><td colspan="1" rowspan="1">3.5"x 2.1"x 0.97"</td><td colspan="1" rowspan="1">2.8"x 2.35"x 0.77"</td></tr><tr><td colspan="1" rowspan="1">Weight</td><td colspan="1" rowspan="1">2.05 oz (without batteries)</td><td colspan="1" rowspan="1">2.0 oz (without batteries)</td></tr></table>

# J. Standard/Guidance Document Referenced (if applicable):

1. ISO 15197:2003, In Vitro Diagnostic Test Systems - Requirements for Blood Glucose Monitoring Test Systems for Self Managing Diabetes Mellitus.   
2. ISO 14971:2007, Medical Devices - Application of Risk Management to Medical Devices.   
3. EN 13640:2002, Stability Testing of In Vitro Diagnostic Reagents.   
4. IEC 60601-1-2:2004, Medical electrical equipment - Part 1: General requirement for safety; Electromagnetic compatibility -Requirements and tests.   
5. IEC 61010-2-101:2002, Safety Requirements for Electrical Equipment for Measurement, Control, and Laboratory Use - Part 2-101: Particular Requirements for In Vitro Diagnostic (IVD) Medical Equipment.   
6. IEC 60601-1:2005, Medical Electrical Equipment - Part 1: General Requirements for Safety.   
7. CLSI EP7-2A:2005, Interference Testing in Clinical Chemistry.

# K. Test Principle:

The EG V1 Pro Self-Monitoring Blood Glucose System employs a disposable dry reagent strip technology, using glucose dehydrogenase method to quantify glucose. Each test strip features an electrode containing the glucose dehydrogenase (in the presence of the coenzyme: Flavin Adenine Dinucleotide, FAD). A blood sample is applied to the blood collection area at the tip of the strip and is automatically drawn into the reaction zone, where the FAD-binding glucose dehydrogenase catalyzes glucose to dehydrogenate and to produce gluconolactone. During the reaction, a mediator transfers electrons to the electrode surface and generates a current. The amount of the current is proportional to the amount of glucose present in the blood sample. The glucose concentration is calculated in the EG V1 Pro Glucose Meter and displayed on the screen after 5 seconds.

L. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility:

Within-run Precision - The testing was used by venous blood, which was stored in the heparin blood collection tube. Glucose was glucolyzed/spiked to the blood to prepare 6 different levels of glucose concentration: $2 0 { \cdot } 5 0 \mathrm { m g / d L }$ , 51-110 mg/dL, 111-150 mg/dL, 151-250 mg/dL, 251-400 mg/dL, and $4 0 1 { \sim } 6 0 0 ~ \mathrm { m g / d L }$ . For each testing range, 10 meters, 10 pcs of test strips for each meter, and 2 lots of test strips were used. $N = 1 0$ Meters $\tt { \tt { x 1 0 } }$ tests x 2 lots $= 2 0 0$ )

<table><tr><td rowspan=2 colspan=1>Range (mg/dL)</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=3>EG V1 SMBG system</td></tr><tr><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>20~50mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>40.7</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>6.5%</td></tr><tr><td rowspan=1 colspan=1>51~110 mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>108.5</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=1 colspan=1>111~150 mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>137.0</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>151~250 mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>223.5</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>2.9%</td></tr><tr><td rowspan=1 colspan=1>251~400 mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>399.8</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>2.8%</td></tr><tr><td rowspan=1 colspan=1>401~600 mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>512.1</td><td rowspan=1 colspan=1>13.9</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=1 colspan=1>Level 2 control solution</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>118.2</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>2.8%</td></tr></table>

Day-to-Day Precision - 10 Meters, 2 lots of test strips, and 3 control solutions (Level 1, 2, and 3) were prepared. Each control was tested twice a day, once in the morning and once in the afternoon consecutively for 10 days.   
$N = 1 0$ Meter $\times 2$ Lots $\times 2$ tests $\yen 10$ days $\tt a 0 0$ )

<table><tr><td rowspan=1 colspan=1>Controlsolution</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>mean(mg/dL)</td><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>41.8</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>7.5%</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>120.7</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>349.8</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>2.1%</td></tr></table>

b.Linearity assay reportable range:

A $2 5 m L$ venous whole blood sample was treated with heparin vacuum tube. The blood supplemented with $\beta$ -D-glucose to prepare seven different blood glucose levels $( 2 0 { - } 5 0 ~ \mathsf { m g } / \mathsf { d L }$ , 51-80 mg/dL, 81-120 mg/dL, 121-200 mg/dL, 201-300 mg/dL, $3 0 1 { - } 4 0 0 ~ \mathrm { m g / d L }$ , and $4 0 0 { \cdot } 6 0 0 \mathrm { m g / d L } )$ . A total of 630 tests were performed to determine the linear regression in three test strip lots.

For each strip lot, ${ \sf N } = 3$ tests/day $\pmb { \chi }$ 10 days x 7 glucose ranges $\mathtt { \mathtt { = } } 2 1 0$

The linear regression was as follows:

<table><tr><td rowspan=1 colspan=1>N=</td><td rowspan=1 colspan=1>630 (210X3Lot)</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.9809</td></tr><tr><td rowspan=1 colspan=1>Y-intercept</td><td rowspan=1 colspan=1>0.8180</td></tr><tr><td rowspan=1 colspan=1>2R</td><td rowspan=1 colspan=1>0.9973</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The device was traceable to a laboratory YSI 2300D analyzer. The YSI 2300D analyzer was calibrated before use and the calibrator was manufactured gravimetrically and provided from the instrument supplier. The YSl 2300D analyzer is validated by using the international standard reference material (NIST 965b) every year.

Stability characteristics of the level 2 and level 3 control solutions were determined by performing real-time stability studies and the shelf life could be up to 19 months

at the room temperature.

d.Detection limit:

Data was provided to support a reportable range of $2 0 { \cdot } 6 0 0 ~ \mathsf { m g } / \mathsf { d L }$

Analytical specificity:

Hematocrit interference was evaluated by adjusting the glucose and hematocrit levels of venous blood samples from several donors. The venous blood samples were glucolyzed/spiked to 4 glucose concentrations and the hematocrit levels were adjusted to $20 \%$ , $30 \%$ , $40 \%$ , $50 \%$ and $60 \%$ . For each hematocrit level, the linear regression was determined by 40 testing results, $N = 2$ times $\times 5$ meters x 4 glucose ranges $\tt { \tt = 4 0 }$ . The maximum percent bias was calculated by comparing to the YSI reading and shown on each linear regression. The acceptance criteria of Hematocrit interference test is: bias $\leq 1 5 \ m g / \mathrm d L$ when glucose concentration $\mathtt { < } 7 5$ mg/dL and bias $\leq 1 5 \%$ when glucose concentration $\geq 7 5 m g / d L$ . Results were summarized in the following table. The device was claimed to use blood samples having hematocrit concentrations ranging from $20 \%$ to $60 \%$ .

<table><tr><td rowspan=1 colspan=1>Strip lot #</td><td rowspan=1 colspan=1>Hematocrit %</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Y-intercept</td><td rowspan=1 colspan=1>R^{2</td><td rowspan=1 colspan=1>% Bias</td></tr><tr><td rowspan=5 colspan=1>012072901</td><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>1.1302</td><td rowspan=1 colspan=1>-0.1549</td><td rowspan=1 colspan=1>0.9994</td><td rowspan=1 colspan=1>11.5</td></tr><tr><td rowspan=1 colspan=1>30%</td><td rowspan=1 colspan=1>1.1020</td><td rowspan=1 colspan=1>-1.2248</td><td rowspan=1 colspan=1>0.9992</td><td rowspan=1 colspan=1>8.2</td></tr><tr><td rowspan=1 colspan=1>41%</td><td rowspan=1 colspan=1>0.9581</td><td rowspan=1 colspan=1>6.7717</td><td rowspan=1 colspan=1>0.9967</td><td rowspan=1 colspan=1>-0.3</td></tr><tr><td rowspan=1 colspan=1>49%</td><td rowspan=1 colspan=1>0.8948</td><td rowspan=1 colspan=1>-0.6686</td><td rowspan=1 colspan=1>0.9984</td><td rowspan=1 colspan=1>-9.9</td></tr><tr><td rowspan=1 colspan=1>60%</td><td rowspan=1 colspan=1>0.8800</td><td rowspan=1 colspan=1>-1.9043</td><td rowspan=1 colspan=1>0.9994</td><td rowspan=1 colspan=1>-11.7</td></tr><tr><td rowspan=5 colspan=1>012072701</td><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>1.1257</td><td rowspan=1 colspan=1>0.1220</td><td rowspan=1 colspan=1>0.9992</td><td rowspan=1 colspan=1>11.3</td></tr><tr><td rowspan=1 colspan=1>30%</td><td rowspan=1 colspan=1>1.0620</td><td rowspan=1 colspan=1>7.2361</td><td rowspan=1 colspan=1>0.9994</td><td rowspan=1 colspan=1>9.4</td></tr><tr><td rowspan=1 colspan=1>41%</td><td rowspan=1 colspan=1>1.0009</td><td rowspan=1 colspan=1>1.1845</td><td rowspan=1 colspan=1>0.9977</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>49%</td><td rowspan=1 colspan=1>0.8875</td><td rowspan=1 colspan=1>-0.7334</td><td rowspan=1 colspan=1>0.9991</td><td rowspan=1 colspan=1>-10.3</td></tr><tr><td rowspan=1 colspan=1>60%</td><td rowspan=1 colspan=1>0.8674</td><td rowspan=1 colspan=1>-1.9611</td><td rowspan=1 colspan=1>0.9991</td><td rowspan=1 colspan=1>-13.1</td></tr></table>

f. Assay cut-off: N/A

# 2. System Accuracy studies:

a. Accuracy/Method comparison with predicate device at sites 1, 2, and 3:

A total 153 diabetes patients were taken capillary blood from a fingertip, palm, and forearm using the EG V1 Pro system at three sites. A healthcare professional performed the tests using the EG V1 Pro meter and the YSI 2300 analyzer. The glucose range of testing values among these samples was $5 0 { \cdot } 5 1 7 \mathrm { m g } / \mathrm { d L }$ . Meter versus YSI at each site met the ISO 15197 requirement of ninety-five percent $(9 5 \% )$ of the individual glucose results falling within $\pm 1 5 \mathrm { m g / d L }$ of the laboratory test at glucose concentrations $< 7 5 m g / d L$ and within $\pm 2 0 \%$ at glucose concentrations $\geq 7 5 \ m g / d L$ . These results were summarized in the following tables.

System accuracy professional results for glucose concentrations < 75 mg/dL

<table><tr><td rowspan=1 colspan=1>Within ±5mg/dL</td><td rowspan=1 colspan=1>Within ±10mg/dL</td><td rowspan=1 colspan=1>Within ±15mg/dL</td></tr><tr><td rowspan=1 colspan=1>16/19 (84.21%)</td><td rowspan=1 colspan=1>17/19 (89.47%)</td><td rowspan=1 colspan=1>19/19 (100%)</td></tr></table>

System accuracy professional results for glucose concentrations ≥ 75 mg/dL

<table><tr><td rowspan=1 colspan=1>Within ±5%</td><td rowspan=1 colspan=1>Within ±10%</td><td rowspan=1 colspan=1>Within ±15%</td><td rowspan=1 colspan=1>Within ±20%</td></tr><tr><td rowspan=1 colspan=1>102/134(76.12%)</td><td rowspan=1 colspan=1>125/134(93.28%)</td><td rowspan=1 colspan=1>129/134(96.27%)</td><td rowspan=1 colspan=1>132/134(98.51%)</td></tr></table>

Method comparison studies were performed by using alternative site testing (AST) samples compared to YSl. The AST samples from the thenar, hypothenar, and forearm taken by a professional were tested. Each linear regression was calculated and shown in the following table:

<table><tr><td rowspan=1 colspan=1>Comparison</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range(mg/dL)</td><td rowspan=1 colspan=1>Range(mg/dL) Slope and Y-intercept</td><td rowspan=1 colspan=1>$R^{}$</td></tr><tr><td rowspan=1 colspan=1>Finger(professional) vs. YSI</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>58.5 - 433.5</td><td rowspan=1 colspan=1>Y=1.0190X-2.9299</td><td rowspan=1 colspan=1>0.9823</td></tr><tr><td rowspan=1 colspan=1>Thenar(professional) vs. YSI</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>55 - 459</td><td rowspan=1 colspan=1>Y=1.0101X-0.6506</td><td rowspan=1 colspan=1>0.9719</td></tr><tr><td rowspan=1 colspan=1>Hypothenar(professional) vs. YSI</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>53 -517</td><td rowspan=1 colspan=1>Y=1.0537X-7.1471</td><td rowspan=1 colspan=1>0.9673</td></tr><tr><td rowspan=1 colspan=1>Forearm(professional) vs. YSI</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>50 - 514</td><td rowspan=1 colspan=1>Y=1.0282 X-3.9814</td><td rowspan=1 colspan=1>0.9650</td></tr><tr><td rowspan=1 colspan=1>Venous vs. YSI</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>59 - 432</td><td rowspan=1 colspan=1>Y=0.9874 X+1.5835</td><td rowspan=1 colspan=1>0.9744</td></tr></table>

The comparison with the predicate device, the linear regressions was as follows: EG V1 Pro vs. predicate device: $\mathsf { Y } = 0 . 9 8 5 9 \mathsf { X } + 3 . 5 6 3 2$ , $\mathbb { R } ^ { 2 } = 0 . 9 3 8 7$

b. Matrix comparison: N/A

Clinical studies:

aClinical Sensitivity: N/A   
Clinical specificity: N/A   
c.Other clinical supportive data (when a. and b. are not applicable): see section 2.a.

4.Clinical cut-off: N/A

5. Expected values/Reference range:

6The expected blood glucose levels for an adult (referenced from American Diabetes Association. Standards of medical care in diabetes-Table 8. Diabetes care. 2008; \$18.):

Time Before meal or fasting Post -meal

Range (mg/dL) 70-130 Less than 180

7. $P D 1 ^ { \otimes }$ SUPER SANI-CLOTH® Germicidal disposable wipes with EPA registration# 9480-4 was validated demonstrating complete inactivation of live virus. It demonstrated that there was no change in performance or in the external materials of the meter and lancing device after 11,000 cleaning and disinfection cycles designed to simulated 3 years for professional use.

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The EG V1 Pro Self Monitoring Blood Glucose System has the same intended use and similar technological characteristics as the Bayer Contour Self Monitoring Blood Glucose System (k062058) marketed by BAYER HEALTHCARE. Moreover, bench testing contained in the submission demonstrated that any differences in their technological characteristics do not raise any new questions of safety or effectiveness. Thus, the EG V1 Pro Self-Monitoring Blood Glucose System is substantially equivalent to the predicate devise.

# 510(k) SUMMARY for EG V1 (BL) Self Monitoring Glucose Test System

A. Submitter's information Company: EPS Bio Technology Corp. Address: No. 8, R&D RD. III, Hsinchu Science Park Hsinchu City, Taiwan, R.O.C. Contact Name: Mr. Y.C. Lei, General Manager Phone: 886-3-6686868 Fax: 886-3-6686866

B. Measured: Glucose

C. Type of Test: Quantitative; electrochemical biosensor

D. Proprietary and Established Names: EG V1 (BL) Self-Monitoring Blood Glucose Test System

E. Common or Usual Name: Glucose Test System

F. Regulatory Information:

1.Regulation section: 21 CFR 862.1345, Glucose Test System 21 CFR 862.1660, Quality control materials (assayed and unassayed)

Classification: Class II Class I, reserved

3.Product code: NBW, System Test, Blood Glucose, Over the Counter LFR, Glucose Dehydrogenase, Glucose JJX, Single (Specified) Controls (assayed and Unassayed)

4. Panel: Chemistry 75

# G. Intended Use:

1.Intended use(s): See Indications for Use below

2. Indication(s) for use:

The EG V1 (BL) Self Monitoring Blood Glucose Test System is intended for the quantitative measurement of glucose in fresh capillary whole blood from fingertip, palm, or forearm. Testing is done outside the body (In Vitro diagnostic use). It is indicated for use at home (over the counter [OTC]) by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. The system is not to be used on neonates, nor for the diagnosis of, or screening for diabetes mellitus. Alternative site testing can be only used during steady-state blood glucose conditions.

The system consists of the EG V1 (BL) meter and the EG test strips. The EG V1 (BL meter only is used with the EG V1 test strips to quantitatively measure glucose in fresh capillary whole blood from fingertip, palm, or forearm.

The EG Glucose Control Solution   
For use with EG V1(BL) Blood Glucose Self Monitoring System as a quality control check to verify the accuracy of blood glucose test results.

3. Special conditions for use statement(s):

EG V1 (BL) Self Monitoring Blood Glucose Test System:

For Over-the-Counter use. Not for use with newborns.

Alternative site testing (AsT) can only be used during steady-state blood glucose conditions. AST (forearm) should only be performed under the following conditions:

$\spadesuit$ Testing before a meal.   
$\cdot$ In a fasting state.   
$\blacktriangle$ Two hours or more after a meal.   
$\spadesuit$ Two hours or more after insulin dosing.   
$\bullet$ Two hours after physical activity.

Measurements from alternative site testing should never be used to calibrate a continuous glucose monitor (CGM) or entered into insulin dose calculators for insulin dosing recommendations.

4. Special instrument requirements: EG V1(BL) Blood Glucose Meter.

# H. Device Description:

The EG V1 (BL) Self-Monitoring Blood Glucose System consists of the EG V1 (BL) Blood Glucose Meter, EG Glucose Test Strips, Auto-Lancet Device and EG Level 2 Control Solution. (Please refer to the IFU for the product picture)

I. Substantial Equivalence Information:

1. Predicate device name(s): ASCENSIA CONTOUR BLOOD GLUCOSE METER, MODEL 7151; REAGENT STRIP, MODEL 7080

Device Company BAYER HEALTHCARE

3. Predicate 510(k) number(s): k062058

4. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Detection method</td><td rowspan=1 colspan=1>Amperometry</td><td rowspan=1 colspan=1>Amperometry</td></tr><tr><td rowspan=1 colspan=1>Enzyme</td><td rowspan=1 colspan=1>Glucose Dehydrogenase(FAD)</td><td rowspan=1 colspan=1>Glucose Dehydrogenase(FAD)</td></tr><tr><td rowspan=1 colspan=1>Sample volume</td><td rowspan=1 colspan=1>&gt; 0.6 uL</td><td rowspan=1 colspan=1>&gt; 0.6 uL</td></tr><tr><td rowspan=1 colspan=1>Temperature range</td><td rowspan=1 colspan=1>10-40°C</td><td rowspan=1 colspan=1>10-40°C</td></tr><tr><td rowspan=1 colspan=1>Memory capability</td><td rowspan=1 colspan=1>480 tests with date andtime</td><td rowspan=1 colspan=1>480 tests with date andtime</td></tr><tr><td rowspan=1 colspan=1>Hematocrit range</td><td rowspan=1 colspan=1>20-60%</td><td rowspan=1 colspan=1>20-60%</td></tr><tr><td rowspan=1 colspan=1>Power</td><td rowspan=1 colspan=1>3V CR2032 batteries</td><td rowspan=1 colspan=1>3V CR2032 batteries</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Test range</td><td rowspan=1 colspan=1>20-600 mg/dL</td><td rowspan=1 colspan=1>10-600mg/dL</td></tr><tr><td rowspan=1 colspan=1>Anatomical Sites</td><td rowspan=1 colspan=1>Venous sample andCapillary samples from thefingertip, palm, forearm,</td><td rowspan=1 colspan=1>Capillary samples from thefingertip, palm, forearm,abdomen and thigh</td></tr><tr><td rowspan=1 colspan=1>Test time</td><td rowspan=1 colspan=1>5 seconds</td><td rowspan=1 colspan=1>8 seconds</td></tr><tr><td rowspan=1 colspan=1>Size L x W x H (inch)</td><td rowspan=1 colspan=1>3.5&quot;x 2.1&quot;x 0.97&quot;</td><td rowspan=1 colspan=1>2.8&quot;x 2.35&quot;x 0.77&quot;</td></tr><tr><td rowspan=1 colspan=1>Weight</td><td rowspan=1 colspan=1>2.05 oz (without batteries)</td><td rowspan=1 colspan=1>2.0 oz (without batteries)</td></tr></table>

J. Standard/Guidance Document Referenced (if applicable):

1. ISO 15197:2003, In Vitro Diagnostic Test Systems - Requirements for Blood Glucose Monitoring Test Systems for Self Managing Diabetes Mellitus.   
2. ISO 14971:2007, Medical Devices - Application of Risk Management to Medical Devices.   
3. EN 13640:2002, Stability Testing of In Vitro Diagnostic Reagents.   
4. IEC 60601-1-2:2004, Medical electrical equipment - Part 1: General requirement for safety; Electromagnetic compatibility -Requirements and tests.   
5. IEC 61010-2-101:2002, Safety Requirements for Electrical Equipment for Measurement, Control, and Laboratory Use - Part 2-101: Particular Requirements for In Vitro Diagnostic (IVD) Medical Equipment.   
6. IEC 60601-1:2005, Medical Electrical Equipment - Part 1: General Requirements for Safety.   
7. CLSI EP7-2A:2005, Interference Testing in Clinical Chemistry.

# K. Test Principle:

The EG V1 (BL) Self-Monitoring Blood Glucose System employs a disposable dry reagent strip technology, using glucose dehydrogenase method to quantify glucose. Each test strip features an electrode containing the glucose dehydrogenase (in the presence of the coenzyme: Flavin Adenine Dinucleotide, FAD). A blood sample is applied to the blood collection area at the tip of the strip and is automatically drawn into the reaction zone, where the FAD-binding glucose dehydrogenase catalyzes glucose to dehydrogenate and to produce gluconolactone. During the reaction, a mediator transfers electrons to the electrode surface and generates a current. The amount of the current is proportional to the amount of glucose present in the blood sample. The glucose concentration is calculated in the EG V1 (BL) Glucose Meter and displayed on the screen after 5 seconds.

# L. Performance Characteristics (if/when applicable):

1. Analytical performance:

a.Precision/Reproducibility:

Within-run Precision - The testing was used by venous blood, which was stored in the heparin blood collection tube. Glucose was glucolyzed/spiked to the blood to prepare 6 different levels of glucose concentration: 20-50 mg/dL, 51-110 mg/dL, 111-150 mg/dL, 151-250 mg/dL, 251-400 mg/dL, and $4 0 1 { \sim } 6 0 0 \mathrm { m g / d L } .$ For each testing range, 10 meters, 10 pcs of test strips for each meter, and 2 lots of test strips were used. $( N = 1 0$ Meters x10 tests x 2 lots $= 2 0 0 )$

<table><tr><td rowspan=2 colspan=1>Range (mg/dL)</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=3>EG V1 SMBG system</td></tr><tr><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>20~50 mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>40.7</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>6.5%</td></tr><tr><td rowspan=1 colspan=1>51~110 mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>108.5</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=1 colspan=1>111~150 mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>137.0</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>151~250 mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>223.5</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>2.9%</td></tr><tr><td rowspan=1 colspan=1>251~400 mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>399.8</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>2.8%</td></tr><tr><td rowspan=1 colspan=1>401~600 mg/dL</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>512.1</td><td rowspan=1 colspan=1>13.9</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=1 colspan=1>Level 2 control solution</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>118.2</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>2.8%</td></tr></table>

Day-to-Day Precision - 10 Meters, 2 lots of test strips, and 3 control solutions (Level 1, 2, and 3) were prepared. Each control was tested twice a day, once in the morning and once in the afternoon consecutively for 10 days.   
$N = 1 0$ Meter $\times 2$ Lots $\times 2$ tests $\yen 10$ days $\yen 400$

<table><tr><td rowspan=1 colspan=1>Controlsolution</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>mean(mg/dL)</td><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>41.8</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>7.5%</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>120.7</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>349.8</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>2.1%</td></tr></table>

b. Linearity assay reportable range: A $2 5 \mathrm { m L }$ venous whole blood sample was treated with heparin vacuum tube. The blood supplemented with $\beta$ -D-glucose to prepare seven different blood glucose levels $( 2 0 { - } 5 0 ~ \mathsf { m g } / \mathsf { d L }$ , 51-80 mg/dL, 81-120 mg/dL, 121-200 mg/dL, 201-300 mg/dL, EY $3 0 1 { - } 4 0 0 ~ \mathrm { m g / d L }$ , and $4 0 0 { \cdot } 6 0 0 \ m g / \mathrm { d L } )$ . A total of 630 tests were performed to determine the linear regression in three test strip lots. For each strip lot, $N = 3$ tests/day $\pmb { \chi }$ 10 days x 7 glucose ranges $\mathtt { \mathtt { \mathtt { i } } 2 1 0 }$

The linear regression was as follows:

<table><tr><td rowspan=1 colspan=1>N=</td><td rowspan=1 colspan=1>630 (210X3Lot)</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.9809</td></tr><tr><td rowspan=1 colspan=1>Y-intercept</td><td rowspan=1 colspan=1>0.8180</td></tr><tr><td rowspan=1 colspan=1>2R</td><td rowspan=1 colspan=1>0.9973</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The device was traceable to a laboratory YSI 2300D analyzer. The YSI 2300D analyzer was calibrated before use and the calibrator was manufactured gravimetrically and provided from the instrument supplier.The YSl 2300D analyzer is validated by using the international standard reference material (NiST 965b) every year.

Stability characteristics of the Level 2 and Level 3 control solutions were determined by performing real-time stability studies and the shelf life could be up to 19 months at the room temperature.

d.Detection limit:

Data was provided to support a reportable range of 20-600 mg/dL.

Analytical specificity:

Hematocrit interference was evaluated by adjusting the glucose and hematocrit levels of venous blood samples from several donors. The venous blood samples were glucolyzed/spiked to 4 glucose concentrations and the hematocrit levels were adjusted to $20 \%$ , $30 \%$ , $40 \%$ , $50 \%$ and $60 \%$ . For each hematocrit level, the linear regression was determined by 40 testing results, $\Nu = 2$ times $\times 5$ meters x 4 glucose ranges $\mathtt { \mathtt { \mathtt { = 4 0 } } }$ . The maximum percent bias was calculated by comparing to the YSI reading and shown on each linear regression. The acceptance criteria of Hematocrit interference test is: bias $\leq 1 5 \ m g / \mathsf d L$ when glucose concentration $\mathtt { < } 7 5$ mg/dL and bias $\leq 1 5 \%$ when glucose concentration ≥75 mg/dL. Results were summarized in the following table. The device was claimed to use blood samples having hematocrit concentrations ranging from $20 \%$ to $60 \%$ .

<table><tr><td colspan="1" rowspan="1">Strip lot #</td><td colspan="1" rowspan="1">Hematocrit %</td><td colspan="1" rowspan="1">Slope</td><td colspan="1" rowspan="1">Y-intercept</td><td colspan="1" rowspan="1">R^{2}$</td><td colspan="1" rowspan="1">% Bias</td></tr><tr><td colspan="1" rowspan="5">012072901</td><td colspan="1" rowspan="1">20%</td><td colspan="1" rowspan="1">1.1302</td><td colspan="1" rowspan="1">-0.1549</td><td colspan="1" rowspan="1">0.9994</td><td colspan="1" rowspan="1">11.5</td></tr><tr><td colspan="1" rowspan="1">30%</td><td colspan="1" rowspan="1">1.1020</td><td colspan="1" rowspan="1">-1.2248</td><td colspan="1" rowspan="1">0.9992</td><td colspan="1" rowspan="1">8.2</td></tr><tr><td colspan="1" rowspan="1">41%</td><td colspan="1" rowspan="1">0.9581</td><td colspan="1" rowspan="1">6.7717</td><td colspan="1" rowspan="1">0.9967</td><td colspan="1" rowspan="1">-0.3</td></tr><tr><td colspan="1" rowspan="1">49%</td><td colspan="1" rowspan="1">0.8948</td><td colspan="1" rowspan="1">-0.6686I</td><td colspan="1" rowspan="1">0.9984</td><td colspan="1" rowspan="1">-9.9</td></tr><tr><td colspan="1" rowspan="1">60%</td><td colspan="1" rowspan="1">0.8800</td><td colspan="1" rowspan="1">-1.9043</td><td colspan="1" rowspan="1">0.9994</td><td colspan="1" rowspan="1">-11.7</td></tr><tr><td colspan="1" rowspan="5">012072701</td><td colspan="1" rowspan="1">20%</td><td colspan="1" rowspan="1">1.1257</td><td colspan="1" rowspan="1">0.1220</td><td colspan="1" rowspan="1">0.9992</td><td colspan="1" rowspan="1">11.3</td></tr><tr><td colspan="1" rowspan="1">30%</td><td colspan="1" rowspan="1">1.0620</td><td colspan="1" rowspan="1">7.2361</td><td colspan="1" rowspan="1">0.9994</td><td colspan="1" rowspan="1">9.4</td></tr><tr><td colspan="1" rowspan="1">41%</td><td colspan="1" rowspan="1">1.0009</td><td colspan="1" rowspan="1">1.1845</td><td colspan="1" rowspan="1">0.9977</td><td colspan="1" rowspan="1">0.7</td></tr><tr><td colspan="1" rowspan="1">49%</td><td colspan="1" rowspan="1">0.8875</td><td colspan="1" rowspan="1">-0.7334</td><td colspan="1" rowspan="1">0.9991</td><td colspan="1" rowspan="1">-10.3</td></tr><tr><td colspan="1" rowspan="1">60%</td><td colspan="1" rowspan="1">0.8674</td><td colspan="1" rowspan="1">-1.9611</td><td colspan="1" rowspan="1">0.9991</td><td colspan="1" rowspan="1">-13.1</td></tr></table>

f. Assay cut-off: N/A

# 2.System Accuracy studies:

a. Accuracy/Method comparison with predicate device at sites 1, 2, and 3:

A total 153 diabetes patients performed a fingerstick, palm and forearm using the EG V1 (BL) system at three sites. A patient performed the testing using the EG V1 (BL) meter. A healthcare professional performed the test using the YSI 2300 analyzer. The glucose range of testing values among these samples was 50-517 mg/dL.

Meter versus YSl at each site met the ISO 15197 requirement of ninety-five percent $( 9 5 \% )$ of the individual glucose results falling within $\pm 1 5 \mathrm { m g / d L }$ of the laboratory test at glucose concentrations $< 7 5 m g / d L$ and within $\pm 2 0 \%$ at glucose concentrations $\ge 7 5 m g / \mathrm { d L }$ . These results were summarized in the following tables.

System accuracy patient results for glucose concentrations $< 7 5 m g / d L$   

<table><tr><td rowspan=1 colspan=1>Within ±5mg/dL</td><td rowspan=1 colspan=1>Within ±10mg/dL</td><td rowspan=1 colspan=1>Within ±15mg/dL</td></tr><tr><td rowspan=1 colspan=1>14/19 (73.68%)</td><td rowspan=1 colspan=1>19/19 (100%)</td><td rowspan=1 colspan=1>19/19 (100%)</td></tr></table>

System accuracy patient results for glucose concentrations ≥ 75 mg/dL   

<table><tr><td rowspan=1 colspan=1>Within ±5%</td><td rowspan=1 colspan=1>Within ±10%</td><td rowspan=1 colspan=1>Within ±15%</td><td rowspan=1 colspan=1>Within ±20%</td></tr><tr><td rowspan=1 colspan=1>83/134(61.94%)</td><td rowspan=1 colspan=1>115/134(85.82%)</td><td rowspan=1 colspan=1>129/134(96.27%)</td><td rowspan=1 colspan=1>131/134(97.76%)</td></tr></table>

Method comparison studies were performed by using alternative site testing (AST) samples compared to YSl. The AST samples from the thenar, hypothenar, and forearm taken by a patient were tested. Each linear regression was calculated and shown in the following table:

<table><tr><td rowspan=1 colspan=1>Comparison</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range(mg/dL)</td><td rowspan=1 colspan=1>Range(mg/dL) Slope and Y-intercept</td><td rowspan=1 colspan=1>$R^{2}$</td></tr><tr><td rowspan=1 colspan=1>Finger(a patient) vs. YSI</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>58.5 - 433.5</td><td rowspan=1 colspan=1>Y=1.0100X-0.9679</td><td rowspan=1 colspan=1>0.9696</td></tr><tr><td rowspan=1 colspan=1>Thenar(a patient) vs. YSI</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>55 - 459</td><td rowspan=1 colspan=1>Y=0.9688X+4.8241</td><td rowspan=1 colspan=1>0.9481</td></tr><tr><td rowspan=1 colspan=1>Hypothenar(a patient) vs. YSI</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>53 - 517</td><td rowspan=1 colspan=1>Y=1.0896 X-11.7596</td><td rowspan=1 colspan=1>0.9584</td></tr><tr><td rowspan=1 colspan=1>Forearm(a patient) vs. YSI</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>50 - 514</td><td rowspan=1 colspan=1>Y=1.0263X-4.6425</td><td rowspan=1 colspan=1>0.9503</td></tr></table>

The comparison with the predicate device, the linear regressions was as follows: EG V1 (BL) vs. predicate device: $\mathsf { Y } = 0 . 9 8 5 9 \mathsf { X } + 3 . 5 6 3 2$ , $\mathsf { R } ^ { 2 } \boldsymbol { = } \boldsymbol { 0 } . \mathsf { 9 3 8 7 }$

b. Matrix comparison: N/A

Clinical studies:

aClinical Sensitivity: N/A

Clinical specificity: N/A

c.Other clinical supportive data (when a. and b. are not applicable): see section 2.a.

4. Clinical cut-off: N/A

5. Expected values/Reference range:

The expected blood glucose levels for an adult (referenced from American Diabetes Association. Standards of medical care in diabetes-Table 8. Diabetes care. 2008; S18.):

Time Before meals or fasting Post -meals

Range (mg/dL) 70-130 Less than 180

6. $P D | ^ { \otimes }$ SUPER SANI-CLOTH® Germicidal disposable wipes with EPA registration# 9480-4 was validated demonstrating complete inactivation of live virus. It demonstrated that there was no change in performance or in the external materials of the meter and lancing device after 11,000 cleaning and disinfection cycles designed to simulated 4 years for home use.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The EG V1 (BL) Self Monitoring Blood Glucose System has the same intended use and similar technological characteristics as the Bayer Contour Self Monitoring Blood Glucose System (k062058) marketed by BAYER HEALTHCARE. Moreover, bench testing contained in the submission demonstrated that any differences in their technological characteristics do not raise any new questions of safety or effectiveness. Thus, the EG V1 (BL) Self-Monitoring Blood Glucose System is substantially equivalent to the predicate devise.

EPS Bio Technology Corp.   
c/o Y.C. Lei   
No. 8 R&D. Road III, Hsinchu Science Park Hsinchu City, ROC 30077   
Taiwan

Re: k101037 Trade/Device Name: EG V1(BL) Self Monitoring Blood Glucose Test System, EG V1 Pro Self Monitoring Blood Glucose Test System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose Test System Regulatory Class: Class II Product Code: NBW, LFR, JJX Dated: 18 May 2011 Received: 20 May 2011

Dear: Mr. Lei,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and p  hDevva  Sfe  0 0Also, please note the regulation entitled, "Misbranding by reference to premarket   
at  r 0.Fr uets gard e ot ve ve the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

GC.

:

Courthey Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): k101037

Device Name: EG V1 Pro Self Monitoring Blood Glucose Test system

Indication For Use:

The EG V1 Pro Self Monitoring Blood Glucose Test System is intended for the quantitative measurement of glucose in venous whole blood or fresh capillary whole blood from the fingertip. Testing is done outside the body (In Vitro diagnostic use). It is intended for multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of diabetes control. The system is only used with single-use lancing devices. The system is not to be used on neonates, nor for the diagnosis of, or screening for diabetes mellitus.

The system consists of the EG V1 Pro meter and the EG Pro Test Strips. The EG V1 Pro meter only is used with the EG Pro Test Strips to quantitatively measure glucose in venous whole blood or fresh capillary whole blood from the fingertip.

# EG Glucose Control Solution

For use with the EG V1 Pro Blood Glucose Self Monitoring System as a quality control check to verify the accuracy of blood glucose test results.

Prescription Use V And/Or Over the Counter Use V. (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety IVD)

![](images/add3ee54aaa21a2d1ce0c6e3c7f8c6b16046ce4ec89ee12fefe709ce126f5548.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

# Indications for Use

510(k) Number (if known): k101037

Device Name: EG V1(BL) Self Monitoring Blood Glucose Test system

Indication For Use:

The EG V1 (BL) Self Monitoring Blood Glucose Test System is intended for the quantiatative measurement of glucose in fresh capillary whole blood from the fingertip, palm or forearm. Testing is done outside the body (In Vitro diagnostic use). It is indicated for use at home (over the counter[OTC]) by a single patient with diabetes and should not be shared, as an aid to monitor the effectiveness of diabetes control. The system is not to be used on neonates, nor for the diagnosis of, or screening for diabetes mellitus. Alternative site testing can only be used during steady-state blood glucose conditions.

The system consists of the EG V1 (BL) meter and the EG V1 Test Strips. The EG V1 (BL) meter only is used with the EG V1 Test Strips to quantitatively measure glucose in venous whole blood or fresh capillary whole blood from the fingertip, palm, or forearm.

# EG Glucose Control Solution

For use with the EG V1 Pro Blood Glucose Self Monitoring System as a quality control check to verify the accuracy of blood glucose test results.

Prescription Use And/Or Over the Counter Use V (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety 0OIVD)

![](images/21b808229db6e7bea6cc6c5e140727dba79e65e75e60dc35c12c44b0261a0e6d.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety